The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
News|Articles|April 7, 2014
Dalton Pharma Completes Aseptic Filling Capabilities Expansion
Author(s)Pharmaceutical Technology Editors
Dalton Pharma completes its $2.5 million expansion in Toronto for sterile and aseptic filling capabilities.
Advertisement
Dalton Pharma Services
, a privately owned pharmaceutical services provider, reported the completion of a $2.5 million expansion of its sterile and aseptic filling capabilities in Toronto, Canada. This project included addition ofsterile vial processing and washing, expanded vial depyrogenation capability, automated vial inspection capability, a new Water For Injection (WFI) system, and expanded and improved gowning areas for GMP manufacturing operators.
Source:
Dalton Pharma Services
Advertisement
Related to this article
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Shubhajit Paul, a senior research fellow in Boehringer Ingelheim’s Department of Material Analytical Sciences, spoke with PharmTech at AAPS PharmSci 360 to explain how tabletability prediction can be improved for roller-compacted formulations.
This week on PharmTech.com, experts discussed E&L suitability standards, rare disease treatment development, sourcing ingredient suppliers, the use of AI in quality control, and more.
How to test pen injector assembly interfaces from URS to FAT and SAT: verify part tracking, reject confirmation, restarts, and data transfer evidence.
Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
Advertisement
Advertisement